Small biotechs in early development of cell therapies are often surprised by the strictness of commercial manufacturing standards. That’s the view of Luděk Sojka, PhD, CEO of contract developer and manufacturer SCTbio.

Sojka, who spoke at the Terrapinn conference on advanced therapies earlier this year, believes this is why companies should approach a CDMO as early as possible.

“Early-stage biotechs can be really surprised that you need to document everything and describe each step in your process,” he explains. “But the GMP manufacturing standards criteria are very strict.”

Moving from a non-GMP process to a GMP process late in development can be a challenge, he adds, especially for companies with limited prior experience in GMP environments.

“We see a lot of projects from small facilities in academic institutions that already have GMP certification and the documentation in place,” he explains.“But we also have projects from academic environments that don’t have access to a GMP-certified facility, or where the developers want to get started with a CDMO right away.”

 

Starting materials

Another challenge is starting materials. Companies often believe the process of quality control (QC) and releasing batches is simple once they have a process in place. However, in reality, the cells of each patient may behave differently leading to problems with product validation, says Sojka. “You need a very robust process to accommodate the variability of starting materials for autologous CAR-T therapies.”

A CDMO can assist by devising robust QC batch release tests early in development. Sojka believes biotechs can also be unaware of the importance of a close partnership with your CDMO, including agreeing to write down all the details of your manufacturing process.

“There must be trust, you must exchange data, and you must believe in each other,” he emphasizes, and urges biotechs working on cell therapies to approach a CDMO with a track record of working with cells, even if it’s not the exact cell type used in their therapy.

Having a company who can work with them to source starting materials and distribute their product is also important, according to Sojka.

Source:
https://www.genengnews.com/topics/bioprocessing/cell-therapy-developers-should-consider-gmp-manufacturing-early/
GMP mRNA
Check out our AAV CDMO service to expedite your gene therapy research
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Future Of Gamma Delta T Cell Therapies

Gamma delta T cell-based immunotherapies have emerged as a promising frontier in cancer treatment and beyond, building on the success of chimeric antigen receptor T-cell (CAR T cell) therapy and expanding on the potential of the immune system as a therapeutic...

read more

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
READ MORE

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
READ MORE
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.
READ MORE